Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial
The present trial aimed to investigate the effects of pioglitazone on the serum level of asymmetric dimethylarginine (ADMA), a marker of endothelial function, and some indices of inflammation and glucose and lipid metabolism in nondiabetic metabolic syndrome patients. 104 eligible participants (57%...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2013/358074 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551477349974016 |
|---|---|
| author | Pedram Shokouh Adel Joharimoghadam Hamidreza Roohafza Masoumeh Sadeghi Allahyar Golabchi Maryam Boshtam Nizal Sarrafzadegan |
| author_facet | Pedram Shokouh Adel Joharimoghadam Hamidreza Roohafza Masoumeh Sadeghi Allahyar Golabchi Maryam Boshtam Nizal Sarrafzadegan |
| author_sort | Pedram Shokouh |
| collection | DOAJ |
| description | The present trial aimed to investigate the effects of pioglitazone on the serum level of asymmetric dimethylarginine (ADMA), a marker of endothelial function, and some indices of inflammation and glucose and lipid metabolism in nondiabetic metabolic syndrome patients. 104 eligible participants (57% female; age between 20 and 70) were enrolled in a double-blind placebo-controlled trial and were randomized to receive either pioglitazone (uptitrated to 30 mg/day) or matching placebo for 24 weeks. Participants were clinically examined and a blood sample was obtained at baseline and at the end of the trial. Pioglitazone significantly improved C-reactive protein level irrespective of changes in insulin sensitivity. Compared with the placebo group, alanine and aspartate transaminases were decreased and high-density lipoprotein cholesterol was increased after treatment with pioglitazone. A considerably greater weight gain was also recorded in the intervention group. We failed to observe any significant changes in serum ADMA in either group and between groups with and without adjustment for age, sex, and components of the metabolic syndrome. In a nutshell, pioglitazone seems to have positive effects on lipid profile, liver transaminases, and systemic inflammation. However, its previously demonstrated endothelial function-improving properties do not seem to be mediated by ADMA. |
| format | Article |
| id | doaj-art-9cda686b9d0b4740a9b832611c51643b |
| institution | Kabale University |
| issn | 1687-4757 1687-4765 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-9cda686b9d0b4740a9b832611c51643b2025-02-03T06:01:28ZengWileyPPAR Research1687-47571687-47652013-01-01201310.1155/2013/358074358074Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical TrialPedram Shokouh0Adel Joharimoghadam1Hamidreza Roohafza2Masoumeh Sadeghi3Allahyar Golabchi4Maryam Boshtam5Nizal Sarrafzadegan6AJA University of Medical Sciences, Tehran 1411718541, IranAJA University of Medical Sciences, Tehran 1411718541, IranCardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan 81465-1148, IranCardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan 81465-1148, IranCardiac Electrophysiology Research Center, Rajaie Cardiovascular Medical and Research Center, Tehran University of Medical Sciences, Tehran 19969-11151, IranCardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan 81465-1148, IranCardiovascular Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan 81465-1148, IranThe present trial aimed to investigate the effects of pioglitazone on the serum level of asymmetric dimethylarginine (ADMA), a marker of endothelial function, and some indices of inflammation and glucose and lipid metabolism in nondiabetic metabolic syndrome patients. 104 eligible participants (57% female; age between 20 and 70) were enrolled in a double-blind placebo-controlled trial and were randomized to receive either pioglitazone (uptitrated to 30 mg/day) or matching placebo for 24 weeks. Participants were clinically examined and a blood sample was obtained at baseline and at the end of the trial. Pioglitazone significantly improved C-reactive protein level irrespective of changes in insulin sensitivity. Compared with the placebo group, alanine and aspartate transaminases were decreased and high-density lipoprotein cholesterol was increased after treatment with pioglitazone. A considerably greater weight gain was also recorded in the intervention group. We failed to observe any significant changes in serum ADMA in either group and between groups with and without adjustment for age, sex, and components of the metabolic syndrome. In a nutshell, pioglitazone seems to have positive effects on lipid profile, liver transaminases, and systemic inflammation. However, its previously demonstrated endothelial function-improving properties do not seem to be mediated by ADMA.http://dx.doi.org/10.1155/2013/358074 |
| spellingShingle | Pedram Shokouh Adel Joharimoghadam Hamidreza Roohafza Masoumeh Sadeghi Allahyar Golabchi Maryam Boshtam Nizal Sarrafzadegan Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial PPAR Research |
| title | Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial |
| title_full | Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial |
| title_fullStr | Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial |
| title_full_unstemmed | Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial |
| title_short | Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial |
| title_sort | effects of pioglitazone on asymmetric dimethylarginine and components of the metabolic syndrome in nondiabetic patients epicamp study a double blind randomized clinical trial |
| url | http://dx.doi.org/10.1155/2013/358074 |
| work_keys_str_mv | AT pedramshokouh effectsofpioglitazoneonasymmetricdimethylarginineandcomponentsofthemetabolicsyndromeinnondiabeticpatientsepicampstudyadoubleblindrandomizedclinicaltrial AT adeljoharimoghadam effectsofpioglitazoneonasymmetricdimethylarginineandcomponentsofthemetabolicsyndromeinnondiabeticpatientsepicampstudyadoubleblindrandomizedclinicaltrial AT hamidrezaroohafza effectsofpioglitazoneonasymmetricdimethylarginineandcomponentsofthemetabolicsyndromeinnondiabeticpatientsepicampstudyadoubleblindrandomizedclinicaltrial AT masoumehsadeghi effectsofpioglitazoneonasymmetricdimethylarginineandcomponentsofthemetabolicsyndromeinnondiabeticpatientsepicampstudyadoubleblindrandomizedclinicaltrial AT allahyargolabchi effectsofpioglitazoneonasymmetricdimethylarginineandcomponentsofthemetabolicsyndromeinnondiabeticpatientsepicampstudyadoubleblindrandomizedclinicaltrial AT maryamboshtam effectsofpioglitazoneonasymmetricdimethylarginineandcomponentsofthemetabolicsyndromeinnondiabeticpatientsepicampstudyadoubleblindrandomizedclinicaltrial AT nizalsarrafzadegan effectsofpioglitazoneonasymmetricdimethylarginineandcomponentsofthemetabolicsyndromeinnondiabeticpatientsepicampstudyadoubleblindrandomizedclinicaltrial |